• BMB Reports
• /
• 제29권5호
• /
• pp.429-435
• /
• 1996

To investigate the structure-antagonistic relationship of the cyclohexapeptide L-659,877, a selective NK-2 tachykinin receptor antagonist, seven analogues were chemically synthesized by a solid phase method. The agonistic and antagonistic activities of the analogues were evaluated by contraction assay using the smooth muscle of guinea pig trachea (GPT) containing the NK-2 receptor. It was shown that the aromatic ring of Phe at position 3 and the sulfur group of Met at position 6 in L-659,877 were essential for binding to the NK-2 receptor. Decrease in antagonistic activity of L-659,877 caused by substituting Leu for Nle at position 5 indicates that the ${\gamma}$ methyl group and side chain length of Leu plays an important role in its antagonistic action. Although the activity was slightly lower than L-659,877, cyclo $[{\beta}Ala^{8}]NKA(4-10)$ (analogue 1) showed potential antagonistic activity for the NK-2 receptor. It was confirmed that the expansion of the ring in L-659,877 by substitution of ${\beta}Ala$ for Gly at position 4 stabilized its conformation monitored by CD spectra. The results suggest that analogue 1 can be used as a new leader compound to design a more powerful, selective, and stable NK-2 receptor antagonist.

• 대한수의학회지
• /
• 제43권3호
• /
• pp.405-414
• /
• 2003

The purpose of this study was to assess the role of tachykinins (TK) in mediating nonadrenergic noncholinergic (NANC) contractions produced by electrical field stimulation (EFS) in the longitudinal muscle of the rat ileum. In the presence of atropine ($1{\mu}M$), guanethidine ($5{\mu}M$), and L-nitroarginine (L-NNA, $200{\mu}M$), EFS (0.5ms pulse duration, 120 V, 1-20 Hz for 2 min) produced a frequency-dependent slowly-developing tonic contraction with superimposed phasic contractions ('on'-contraction) followed by off slowly-decreasing tonic and superimposed phasic contractions ('off'-contraction) of mucosa-free longitudinal oriented muscle strip. These EFS induced responses were blocked by tetrotoxin. $NK_1$ receptor selective antagonist L-732,138 strongly inhibited the EFS-induced excitatory responses. However $NK_2$ receptor selective antagonist, GR 159897 and $NK_3$ receptor selective antagonist SB 222200 did not significantly inhibited the responses. $NK_1$ receptor selective agonist [$Sar^9$,$Met(O_2)^{11}$] Substance P and $NK_2$ receptor selective agonist [${\beta}-Ala^8$]-neurokinin A (4-10) induced tonic contraction with superimposed phasic contractions of longitudinal oriented muscle strip and almost blocked by selective antagonist L-732,138 and GR 159897, respectively. But $NK_3$ receptor selective agonist senktide did not showed any effect. Nifedipine ($1{\mu}M$) abolished the contraction produced either by EFS or by the TK receptor agonists [$Sar^9$,$Met(O_2)^{11}$] Substance P or [${\beta}-Ala^8$]-neurokinin A (4-10). It is concluded that, in the longitudinal muscle of rat ileum, both $NK_1$ and $NK_2$ receptors modulated the responses to exogenous tachykinins, whereas $NK_1$ is mainly involved in NANC neuromuscular contraction.

• The Korean Journal of Pain
• /
• 제35권2호
• /
• pp.173-182
• /
• 2022

Background: Neurokinin-1 (NK1) and calcitonin gene-related peptide (CGRP) play a vital role in pain pathogenesis, and these proteins' antagonists have attracted attention as promising pharmaceutical candidates. The authors investigated the anti-nociceptive effect of co-administration of the CGRP antagonist and an NK1 antagonist on pain models compared to conventional single regimens. Methods: C57Bl/6J mice underwent sciatic nerve ligation for the neuropathic pain model and were injected with 4% formalin into the hind paw for the inflammatory pain model. Each model was divided into four groups: vehicle, NK1 antagonist, CGRP antagonist, and combination treatment groups. The NK1 antagonist aprepitant (BIBN4096, 1 mg/kg) or the CGRP antagonist olcegepant (MK-0869, 10 mg/kg) was injected intraperitoneally. Mechanical allodynia, thermal hypersensitivity, and anxiety-related behaviors were assessed using the von Frey, hot plate, and elevated plus-maze tests. The flinching and licking responses were also evaluated after formalin injection. Results: Co-administration of aprepitant and olcegepant more significantly alleviated pain behaviors than administration of single agents or vehicle, increasing the mechanical threshold and improving the response latency. Anxiety-related behaviors were also markedly improved after dual treatment compared with either naive mice or the neuropathic pain model in the dual treatment group. Flinching frequency and licking response after formalin injection decreased significantly in the dual treatment group. Isobolographic analysis showed a meaningful additive effect between the two compounds. Conclusions: A combination pharmacological therapy comprised of multiple neuropeptide antagonists could be a more effective therapeutic strategy for alleviating neuropathic or inflammatory pain.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1996년도 춘계학술대회
• /
• pp.252-252
• /
• 1996

We Investigated the peripheral excitatory effect of capsaicin and KR-25018, a newly synthesized capsaicin derivative which was demonstrated to have a potent analgesic activity. KR-25018 and capsaicin were found to be both potent efficacious contractors of isolated guinea pig bronchial smooth muscle. KR-25018 was equipotent with capsaicin and [Sar$\^$9/,Met(O$_2$)$\^$11/]-substance P, 10-fold more potent than histamine and 10-fold less potent than (${\beta}$ -Ala$\^$8/)-neurokinin A(4-10), and their -log(M)EC$\_$50/ values were 6.94${\pm}$0.08, 6.86${\pm}$0.05, 6.96${\pm}$0.07, 5.64${\pm}$0.04, 7.96${\pm}$0.02, respectively. Contractile responses to KR-25018 and capsaicin were potentiated by phosphoramidon (1 ${\mu}$M), an inhibitor of neuropeptide-inactivating endopeptidase, but completely abolished in a calcium-free medium. These responses to KR-25018 and capsaicin were unaffected by the NK-1 antagonist CP96345 (1${\mu}$M), partially inhibited by the NK-2 antagonist SR48968 (1 ${\mu}$M) but almost completely abolished by a combination of the antagonists. A vanilloid receptor antagonist capsazepine competitively antagonized the responses to both KR-25018 and capsaicin (pA$_2$: aganst KR-25018, 5.98${\pm}$0.47; against capsaicin, 5.80${\pm}$0.31), and a capsaicin-sensitive cation channel antagonist ruthenium red caused significant reduction in the maximum responses to KR-25018 and capsaicin (pD'$_2$: against KR-25018, 4.61${\pm}$0.33; against capsaicin 4.96${\pm}$0.21). In conclusion, the present results suggest that KR-25018 and cpasaicin act on the same vanilloid receptor inducing the influx of calcium through ruthenium red-sensitive cation channel and produce contractile responses via the release of tachykinins that act on both NK-1 and NK-2 receptor subtypes.

• 한국어병학회지
• /
• 제14권1호
• /
• pp.46-53
• /
• 2001

본 연구에서는 경골어류인 나일틸라피아(Oreochromis niloticus)와 이스라엘잉어(Cyprinus carpio)의 장관에 대한 neurokinin-1(NK-1)수용체 효능제인 substance p(SP)와 neurokinin-2(NK-2)수용체 효능제인 neurokinin A(NKA)의 수축활성과 작용기전을 비교 분석하였다. SP와 NKA는 모두 나일틸라피아와 이스라엘잉어의 장관 평활근에 대하여 농도 의존적인 수축반응을 나타내었다. 그러나 이들에 의한 수축반응의 경향은 어종에 따라 다르게 나타났다. 즉, 나일틸라피아 장관 평활근에 대하여서는 SP가 NKA에 비하여 높은 친화력과 효능을 나타내었으나, 이스라엘잉어의 장관 평활근에 대하여서는 SP와 NKA의 수축반응은 유의한 차이가 없었다. 나일틸라피아 및 이스라엘잉어의 장관 평활근에 대한 SP와 NKA의 수축반응들은 모두 NK-1 수용체 차단제인 L-732,138에 의해서는 비경쟁적으로 길항되었으나, NK-2 수용체 차단제인 MDL 29913에 의해서는 영향을 받지 않았다. 한편, 선택적 무스카린성 수용체 길항제인 atropine($5{\times}10^{-7}$M)및 신경절 차단제인 tetrodotoxin($2{\times}10^{-7}$M)은 나일틸라피아 및 이스라엘잉어의 장관 평활근에 있어서 SP에 의해 유발된 수축반응들은 모두 유의성 있게 억제시켰으나, NKA에 의해 유발된 수축반응들에 대하여서는 유의성 있는 영향을 나타내지 않았다. 이상의 결과들을 종합하여 보면, SP및 NKA는 모두 어류의 장관 평활근에 대하여 강력한 수축효과를 나타내나 그 작용기전은 다르다고 추정된다. 즉, SP및 NKA의 장관 수축작용은 주로 장관 평활근에 존재하는 NK-1 수용체를 매개한 직접적인 작용에 기인하는 것으로 사료되나 SP의 경우에는 tachykinin 수용체를 통한 직접작용 이외에도 콜린성 신경말단(cholinergic nerve terminal)을 자극하는 간접적인 경로도 관여하는 것으로 추정된다.

• 대한화학회지
• /
• 제43권5호
• /
• pp.540-546
• /
• 1999

새로운 NK-2 antagonist이며 고리상 펩티드인 cycIo-($Gln^1-Trp^2-Phe^3-{\beta}Ala^4-Leu^5-Met^6$)의 DMSO 용액 중에서의 형태를 2차원 핵자기공명과 분자동력학적인 계산에 의하여 결정하였다. 조건을 만족시키는 25개의 구조는 모든 아미노산 잔기의 골격원자들 (N,$C^{\alpha}$, C')의 자승 평균 평방근이 $0.02{\AA}$이내로 수렴하였다. 이 고리상 펩티드의 구조는 $Met^6NH$와 $Ala^4CO$, $Ala^4NH$와 $Met^6CO$, $Phe^3NH$와 $Met^6CO$의 사이에 분자내 수소결합이, Gln과 Trp에 type-I ${\beta}$-turn, 그리고 Leu에서 ${\gamma}$-turn을 취하고 있었다. 알려져 있는 고리상 펩티드인 cyclo-($Gln^1-Trp^2-Phe^3-Gly^4-Leu^5-Met^6$)의 Gly이 ${\beta}$Ala으로 바뀜에 따라 ${\beta}$Ala의 여분의 메틸렌이 고리의 골격의 반발력을 완화시키고 수소결합들이 형태의 안정에 기여하고 있다고 생각된다.

• 대한의생명과학회지
• /
• 제11권3호
• /
• pp.375-382
• /
• 2005

This study aimed to investigate whether nociceptin is implicated in the, trigeminovascular responses to electrical stimulation of trigeminal ganglion in rats. An open cranial window was prepared on the right parietal bone of male Sprague-Dawley rats. Trigeminovascular system was stimulated by electrical stimulation of trigeminal ganglion (ETS; 5ms, 5Hz, 3V). Neonatal capsaicin treatment was performed with subcutaneous administration of capsaicin (50mg/kg) within the first 24 hours after birth. Changes in regional cerebral blood flow were continuously measured through the cranial window by laser-Doppler flowmetry, and the expression of nociceptin-like immunoreactivity was determined by immunohistochemistry. ETS caused increases in regional blood flow of pial arteriole in a voltage-dependent manner. ETS markedly and voltage-dependently increased the expression of nociceptin-like immunoreactivity in dura mater ipsilateral rather than contralateral to ETS. The nociceptin-like immunoreactivity was markedly reduced by pretreatments with calcitonin gene-related peptide(8-37) ($CGRP_{8-37},\;a\;CGRP_1$ receptor antagonist), L-733060 (a $NK_1$ receptor antagonist), and $[Nphe^1]$ nociceptin(1-13)$NH_2$ (a selective and competitive nociceptin receptor antagonist) as well as by neonatal capsaicin treatment. These results suggest that the electrical stimulation of trigeminal ganglion causes prominent expression of nociceptin within dura mater, in which not only neuropeptides inducing substance P and CGRP but also nociceptin are implicated in the trigeminovascular responses to electrical trigeminal ganglion stimulation.

• Tuberculosis and Respiratory Diseases
• /
• 제42권5호
• /
• pp.744-751
• /
• 1995

연구배경: 여러 종류의 자극으로 감각신경(C-fiber)의 말단부에서 분비되는 신경단백질인 substance P와 neurokinin A는 기관지 평활근의 수축, 점막의 혈장 유출 및 점액의 과분비를 일으켜 기관지 천식 발병 기전에 중요한 역활을 한다. 이러한 기도 신경단백질은 $NK_1$, $NK_2$, $NK_3$ 등의 3종류의 수용체를 통하여 작용하며, $NK_1$ 수용체에 주로 작용하는 substance P는 기도의 혈관확장과 혈장 유출에 관여하며 $NK_2$ 수용체에 작용하는 neurokinin A는 기도의 수축에 주로 작용하며 기도혈장 유출에도 관여하는 것으로 알려져 있다. 목적: 저지들은 백서의 미주신경인 비교감 및 비부교감 신경을 전기적 자극으로 유발된 기도 혈장 유출에서 $NK_1$과 $NK_2$ 수용체 차단제인 FK224를 이용하여 기도내 신경성 염증에서 혈장유출에 대한 효과를 기도 부위별로 확인하였다. 대상 및 방법: 백서 21마리를 7마리씩 3군으로 나누어 미주신경에 전기적 자극을 하지 않은 대조군(control group), 2분간 자극한 군(NANC2군)과 신경 단백 수용체 차단제인 FK224를 미주신경 자극 전에 사용한 군(FK224군)에서 Evans blue dye를 이용하여 기도 부위별 혈장 유출의 정도를 각 군간에 비교하여 다음과 같은 결과를 얻었다. 결과: 1) 2분간 신경 자극한 군(NANC2군)은 대조군에 비하여 기관에서 49.7(${\pm}2.5$)ng/mg으로 353%, 주기관지에서 38.7(${\pm}2.8$)ng/mg으로 221%의 증가와 말초기관지 19.1(${\pm}1.6$)ng/mg으로 151%로 혈장 유출이 모두 유의하게 높았으며(p<0.05), 주로 상부 기도에서 혈장 유출 정도가 심하였으나, 폐실질은 13.0(${\pm}1.8$)ng/mg, 76%로 대조군과 차이는 없었다(p>0.05). 2) 신경 단백질 수용체 차단제를 사용한 FK224군은 2분간 신경 자극한 군에 비하여 기관에서 24.3(${\pm}2.2$)ng/mg으로 49%, 주기관지에서 22.3(${\pm}1.6$)ng/mg 으로 58%의 억제와 말초기관지 13.3(${\pm}0.8$) ng/mg으로 70%로 혈장 유출이 모두 유의하게 감소되었다(p<0.05). 결론: 이상의 결과에 의하면 백서에서 미주신경(NANC)의 전기적 자극으로 유발된 혈장유출은 기도에서만 발생되고 주로 상부기도에서 혈장유출이 심하며, $NK_1$과 $NK_2$ 수용체 차단제인 FK224를 전처치하여 substance P와 neurokinin A의 수용체 차단으로 기도 혈장 유출이 억제됨을 알 수 있었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권4호
• /
• pp.1661-1675
• /
• 2016

Objectives: Can addition of neurokinin-1 receptor antagonists (NK1-RAs) be considered as an ideal strategy for the prevention of chemotherapy-induced nausea and vomiting (CINV)? Researchers differ on this question. Materials and Methods: Electronic databases were searched for randomized control trials (RCTs) that evaluated the effectiveness and safety of NK1-RAs in preventing CINV. The primary end point was complete response (CR) in the acute, delayed, and overall phases after chemotherapy. Subgroup analyses evaluated the types of NK1-RAs, routines of administration, types of malignancies, regimens used in combination with NK1-RAs, and age of patients included in the studies. The incidences of different types of adverse events were also extracted to estimate the safety of NK1-RAs. Results: A total of 38 RCTs involving 13,923 patients were identified. The CR rate of patients receiving NK-RAs was significantly higher than patients in the control groups during overall phase (70.8% vs 56.0%, P<0.001), acute phase (85.1% vs 79.6%, P<0.001), and delayed phase (71.4% vs 58.2%, P<0.001). There were three studies including patients of children or adolescents, the CR rate was also significantly higher in the treatment group (overall phase: OR=2.807, P<0.001; acute phase: OR=2.863, P =0.012; delayed phase: OR=2.417, P<0.001). For all the other outcomes, patients in the NK1-RAs groups showed improvements compared to the control groups (incidence of nausea: 45.2% vs 45.9%, P<0.001; occurrence of vomiting: 22.6% vs 38.9%, P<0.001; usage of rescue drugs: 23.5% vs 34.1%, P<0.001). The pooled side effects from NK1-RAs did not significantly differ from previous reports and the toxicity rates in patients less than eighteen years old also did not diff between the two groups (P=0.497). However, we found that constipation and insomnia were more common in the patients of control groups, whereas diarrhea and hiccups were more frequently detected in patients receiving NK1-RAs. Conclusions: NK1-RAs improved the CR rate of CINV. They are effective for both adults and children. The use of NK1-RAs might be associated with the appearance of diarrhea and hiccups, while decreasing the possibility of constipation and insomnia.

• 한국임상약학회지
• /
• 제20권1호
• /
• pp.17-23
• /
• 2010

Aprepitant is a substance P/neurokinin-1 (NK1)-receptor antagonist that was approved in 2003 for prevention of CINV. In addition, updated anti-emetic guidelines that include the aprepitant regimen have been published by NCCN and ASCO. However there is scarce clinical data in Korea. The prospective study was performed to evaluate the prevention of high dose cisplatin induced nausea and vomiting in all patients who started high-dose cisplatin-based chemotherapy at our hospital. We checked the nausea severity and vomiting episodes by calling patients within 4 to 5 days after chemotherapy. The retrospective study was performed to compare the prevention of CINV in solid tumor patients who switched their anti-emesis regimen from the standard regimen to the aprepitant regimen. In aprepitant regimen, aprepitant was added to the same anti-emetic regimen used during previous cycles. We checked the nausea, vomiting grades and adverse events in electronic medical records (EMR). In prospective study, 195 patients were included in the analysis. 88.2% of patients achieved a complete response (no emesis and no rescue therapy). In retrospective study, 54 patients were reviewed. With aprepitant regimen, nausea and vomiting grades were improved in 22 patients (40.7%) and in 9 patients (16.7%), respectively. Compared with standard regimen, addition of aprepitant provided superior prevention against CINV in Korean patients receiving highly emetogenic cisplatin-based chemotherapy. Moreover, aprepitant significantly prevented CINV in patients who received the standard regimen to prevent CINV in previous chemotherapy cycles.